These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 38565862)

  • 1. Hepatic extracellular ATP/adenosine dynamics in zebrafish models of alcoholic and metabolic steatotic liver disease.
    Tokumaru T; Apolinario MEC; Shimizu N; Umeda R; Honda K; Shikano K; Teranishi H; Hikida T; Hanada T; Ohta K; Li Y; Murakami K; Hanada R
    Sci Rep; 2024 Apr; 14(1):7813. PubMed ID: 38565862
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Steatotic liver disease predicts cardiovascular disease and advanced liver fibrosis: A community-dwelling cohort study with 20-year follow-up.
    Choe HJ; Moon JH; Kim W; Koo BK; Cho NH
    Metabolism; 2024 Apr; 153():155800. PubMed ID: 38266957
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ALT levels, alcohol use, and metabolic risk factors have prognostic relevance for liver-related outcomes in the general population.
    Männistö V; Salomaa V; Jula A; Lundqvist A; Männistö S; Perola M; Åberg F
    JHEP Rep; 2024 Oct; 6(10):101172. PubMed ID: 39430577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatotic Liver Disease with Increased Alcohol Intake Increase the Risk of Developing Hepatocellular Carcinoma and Incident or Decompensated Cirrhosis: A Korean Nationwide Study.
    Kim GA; Jeong S; Jang H; Lee DH; Joo SK; Kim W
    Liver Cancer; 2024 Aug; 13(4):426-437. PubMed ID: 39114758
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Racial and ethnic differences and the role of unfavorable social determinants of health across steatotic liver disease subtypes in the United States.
    Ochoa-Allemant P; Marrero JA; Serper M
    Hepatol Commun; 2023 Dec; 7(12):. PubMed ID: 38051551
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validation of the new nomenclature of steatotic liver disease in patients with a history of excessive alcohol intake: an analysis of data from a prospective cohort study.
    Israelsen M; Torp N; Johansen S; Hansen CD; Hansen ED; Thorhauge K; Hansen JK; Villesen I; Bech K; Wernberg C; Andersen P; Lindvig KP; Tsochatzis EA; Thiele M; Rinella ME; Krag A;
    Lancet Gastroenterol Hepatol; 2024 Mar; 9(3):218-228. PubMed ID: 38218202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Roles of immune dysregulation in MASLD.
    Dong T; Li J; Liu Y; Zhou S; Wei X; Hua H; Tang K; Zhang X; Wang Y; Wu Z; Gao C; Zhang H
    Biomed Pharmacother; 2024 Jan; 170():116069. PubMed ID: 38147736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characteristics and long-term mortality of individuals with MASLD, MetALD, and ALD, and the utility of SAFE score.
    Sripongpun P; Kaewdech A; Udompap P; Kim WR
    JHEP Rep; 2024 Oct; 6(10):101127. PubMed ID: 39290401
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Steatotic Liver Disease: Metabolic Dysfunction, Alcohol, or Both?
    Staufer K; Stauber RE
    Biomedicines; 2023 Jul; 11(8):. PubMed ID: 37626604
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exploring the landscape of steatotic liver disease in the general US population.
    Ciardullo S; Carbone M; Invernizzi P; Perseghin G
    Liver Int; 2023 Nov; 43(11):2425-2433. PubMed ID: 37592856
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolic Dysfunction-Associated Steatotic Liver Disease and All-Cause and Cause-Specific Mortality.
    Oh R; Kim S; Cho SH; Kim J; Lee YB; Jin SM; Hur KY; Kim G; Kim JH
    Diabetes Metab J; 2024 Aug; ():. PubMed ID: 39197834
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sex-based differences in natural killer T cell-mediated protection against diet-induced steatohepatitis in Balb/c mice.
    Cuño-Gómiz C; de Gregorio E; Tutusaus A; Rider P; Andrés-Sánchez N; Colell A; Morales A; Marí M
    Biol Sex Differ; 2023 Nov; 14(1):85. PubMed ID: 37964320
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolic dysfunction-associated steatotic liver disease (SLD) and alcohol-associated liver disease, but not SLD without metabolic dysfunction, are independently associated with new onset of chronic kidney disease during a 10-year follow-up period.
    Mori K; Tanaka M; Sato T; Akiyama Y; Endo K; Ogawa T; Suzuki T; Aida H; Kawaharata W; Nakata K; Hosaka I; Umetsu A; Hanawa N; Furuhashi M
    Hepatol Res; 2024 Aug; ():. PubMed ID: 39110552
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Natural history of metabolic dysfunction-associated steatotic liver disease.
    Lekakis V; Papatheodoridis GV
    Eur J Intern Med; 2024 Apr; 122():3-10. PubMed ID: 37940495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vitamin D and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Novel Mechanistic Insights.
    Aggeletopoulou I; Tsounis EP; Triantos C
    Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38732118
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Misclassified Alcohol-related Liver Disease is Common in Presumed Metabolic Dysfunction-associated Steatotic Liver Disease and Highly Increases Risk for Future Cirrhosis.
    Nasr P; Wester A; Ekstedt M; Strandberg R; Kechagias S; Shang Y; Widman L; Hagström H
    Clin Gastroenterol Hepatol; 2024 May; 22(5):1048-1057.e2. PubMed ID: 38237695
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inflammation in Steatotic Liver Diseases: Pathogenesis and Therapeutic Targets.
    Qian S; Wang X; Chen Y; Zai Q; He Y
    Semin Liver Dis; 2024 Aug; 44(3):319-332. PubMed ID: 38838739
    [TBL] [Abstract][Full Text] [Related]  

  • 18. COMPARISON OF GUT MICROBIOTA IN ALCOHOLIC AND METABOLIC-DYSFUNCION ASSOCIATED STEATOTIC LIVER DISEASE IN ANIMAL MODELS.
    Perlin CM; Longo L; Thoen RU; Uribe-Cruz C; Álvares-DA-Silva MR
    Arq Gastroenterol; 2024; 61():e23100. PubMed ID: 38511793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterizing alcohol-related and metabolic dysfunction-associated steatotic liver disease cirrhosis via fibrotic pattern analysis.
    Fukushima M; Miyaaki H; Nakao Y; Sasaki R; Haraguchi M; Takahashi K; Ozawa E; Miuma S; Akazawa Y; Soyama A; Eguchi S; Okano S; Nakao K
    Sci Rep; 2024 Oct; 14(1):23679. PubMed ID: 39390024
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Multicomponent Medicinal Product Hepar Compositum Reduces Hepatic Inflammation and Fibrosis in a Streptozotocin- and High-Fat Diet-Induced Model of Metabolic Dysfunction-Associated Steatotic Liver Disease/Metabolic Dysfunction-Associated Steatohepatitis.
    Burmeister Y; Weyer K; Dörre A; Seilheimer B
    Biomedicines; 2023 Dec; 11(12):. PubMed ID: 38137437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.